The first panel at Drug Store News’ 25th annual Industry Issues Summit explored how retailers and pharmacy technology companies are changing the healthcare experience.
The on-body device delivers Udenyca, a biosimilar pegfilgrastim administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.
This screening broadens the Signify Health range of in-home services designed to support earlier detection, diagnosis and management of heart arrhythmias.
The study reveals the impact of a dramatic increase in commercially available biosimilars and progress in the areas of patient accessibility and treatment affordability.